BioNTech Extends Global Reach, Ambition With Kite’s Neoantigen T-Cell Receptor Assets

German Biotech Sets Sights On Cancer Cell Therapies

 
• By Alaric DeArment
  
map
BioNTech is expanding its global footprint with the purchase of Kite Pharma's neoantigen TCR R&D program and manufacturing plant • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business